AVITA Medical has revised its revenue guidance for 2024, now expecting revenues of $64.3 million, down from a previous estimate of $68 million to $70 million. The company anticipates revenue for 2025 to be between $100 million and $106 million, indicating a projected growth of 55% to 65%. AVITA aims for cash flow break-even and GAAP profitability by the fourth quarter of 2025. Meanwhile, Helen of Troy Limited reported its third-quarter fiscal 2025 results, with adjusted earnings per share of $2.67, surpassing the $2.60 estimate. However, consolidated net sales revenue decreased to $530.7 million, a decline of 3.4% year-over-year, and the company expects net sales for the year to be between $1.888 billion and $1.913 billion, reflecting a decline of 5.8% to 4.6%. The gross profit margin improved by 90 basis points to 48.9%. Additionally, Butterfly Network reported a preliminary revenue growth of approximately 35% year-over-year for the fourth quarter of 2024, while T2 Biosystems noted a 37% increase in preliminary product revenues for the same period.